Merck & Co. Collaborates with Atreca to Identify Novel Antibody Targets in Oncology

 Merck & Co. Collaborates with Atreca to Identify Novel Antibody Targets in Oncology

Merck & Co. Collaborates with Atreca to Identify Novel Antibody Targets in Oncology

Shots:

  • Atreca to receive up front and retain rights to develop Abs included in the collaboration with Merck while Merck will get a right-of-first negotiation, if Atreca out-licenses its one or more Abs therapies
  • Following target identification, both the companies have the right to advance therapeutic candidates against the targets identified under the collaboration in the exchange of development & commercial milestones payable by either party
  • Atreca’s lead candidate ATRC-101 has the potential to address unmet medical needs of cancer patients with its anticipated initiation of P-Ib study for a solid tumor in H1’20

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Rasayanika

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post